GROWTH HORMONE AXIS / MATRIX
Same Neighborhood, Different Mechanisms
How a single GHRH analog, a two-receptor combination, and a mitochondrial peptide differ in mechanism, evidence quality, and what remains simply unknown.
The short version
This page lines up CJC-1295, CJC-1295/ipamorelin, and MOTS-c on the dimensions that matter most for reading growth-hormone-axis research honestly: what each one actually does, how strong the human evidence is, and what stage of testing it is at. The short version: two of the three (CJC-1295 and the CJC-1295/ipamorelin combination) work by pushing the pituitary gland to release more growth hormone, through one receptor or two; the third (MOTS-c) works on a completely separate cellular pathway and only shares the metabolic neighborhood. None is FDA-approved. None has a completed large human trial. What follows is exactly where each claim's evidence stops.
The comparison matrix
| Dimension | CJC-1295 | CJC-1295 / Ipamorelin | MOTS-c |
|---|---|---|---|
| Mechanism | GHRH-receptor agonist (single arm) | GHRH-receptor + ghrelin-receptor (GHS-R1a) agonism, two arms | Mitochondrial-derived peptide; folate-cycle inhibition leading to AMPK activation; no GHRH- or ghrelin-receptor involvement |
| Most studied for | GH/IGF-1 pharmacodynamics in healthy adults | Combined GH-pulse pharmacodynamics (largely inferred, not blend-tested) | Skeletal-muscle glucose uptake, exercise capacity, and mitochondrial/metabolic stress response — in mice and rats |
| Evidence base | 5 small early-phase human pharmacology studies [1][2][3][4][5] | No blend-specific trial; class-level reviews plus CJC-1295's own human data and in-vitro/animal work [4][6][7][8][9] | 1 observational human cohort (n=94, ill population) [11]; the rest mouse, rat, and cultured-cell studies [10][12][13][14][15][16] |
| Administration studied | Single and multiple subcutaneous doses in healthy adults [4][5] | Not studied as a blend; components studied separately | Not studied in living humans as an intervention at all |
| Regulatory status | Not approved anywhere; research chemical; reviewed and not recommended for an FDA compounding bulks list | Not approved anywhere; CJC-1295 briefly listed then removed from an interim FDA compounding category | Not approved anywhere; research chemical; no comparable regulatory filing found |
| Key caution | Thin human evidence base, plus a discontinued development program and a cited (unconfirmed) patient death | The sold combination has never itself been tested in a controlled human trial | Essentially the entire evidence base is preclinical, aside from one small, ill-population human association |
Mechanism
CJC-1295 is architecturally the simplest of the three: a single receptor, the GHRH receptor, activated by a peptide engineered for protease resistance and, in the DAC form, covalent albumin binding [8]. CJC-1295/ipamorelin keeps that same GHRH-receptor arm and adds a second, independent receptor — GHS-R1a, the ghrelin receptor — with in-vitro work in transfected cells showing the two pathways together roughly double the cAMP signal produced by the GHRH arm alone [9]. Neither of those two findings has been confirmed in a controlled human trial of the actual combination. MOTS-c shares no receptor with either: it is encoded inside mitochondrial DNA, and its best-characterized action is inhibiting the folate cycle to activate AMPK, with a 2024 study identifying casein kinase 2 as a direct binding target [10]. There is no pituitary involvement in its mechanism at all.
Evidence base and quality
This is where the three separate most sharply. CJC-1295's evidence is five small early-phase human pharmacology studies from 2006-2010, mostly measuring GH and IGF-1 levels or serum biomarkers in a few dozen healthy adults total [2][3][4][5], framed by a 2025 review of the broader GHRH-analog class [1]. None of the five is a therapeutic-outcome trial. The CJC-1295/ipamorelin combination has no blend-specific human trial at all — its case rests on CJC-1295's own data [4], a receptor cross-talk experiment in transfected cells [9], a 2005 rat DAC-chemistry study [8], and two class-level reviews, one of GH secretagogues generally [7] and one of a different GHRH analog (tesamorelin) offered only as read-across context [6]. MOTS-c's evidence is, by a wide margin, the most preclinical of the three: six of its seven core citations are mouse, rat, or isolated-cell studies [10][12][13][14][15][16], and the sole human study is an observational cohort of 94 chronic hemodialysis patients measuring a biomarker association, not an intervention [11].
Regulatory and compliance status
None of the three compounds is approved by the FDA or any other regulator for any human indication. CJC-1295 was reviewed — and not recommended — for an FDA compounding bulks list in 2024, with immunogenicity cited as a concern. CJC-1295 and ipamorelin acetate were briefly added to an interim FDA compounding category in September 2023 and removed the following year after the nominators withdrew. MOTS-c has no comparable regulatory filing on record that this desk found. All three are treated as prohibited substances in elite sport by anti-doping authorities, though the specific list category differs by compound class.
Key caution for each
For CJC-1295, the defining caution is the combination of a thin human evidence base with a discontinued 1990s-2000s development program and a patient death frequently cited alongside it, though never established as caused by the compound. For CJC-1295/ipamorelin, it is that the combination sold and used in research communities has never itself been tested in a controlled trial — every claim about 'the stack' is an inference from its two separate halves. For MOTS-c, it is that essentially the entire evidence base is preclinical: aside from one small, ill-population human cohort study, there is no published human data on what exogenous MOTS-c does at all.